

Publisher: Karger
E-ISSN: 1423-0100|50|1|58-62
ISSN: 0300-5526
Source: Intervirology, Vol.50, Iss.1, 2006-11, pp. : 58-62
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
The aim of this serological study was to demonstrate the extent to which antibodies react against subsequent drift variants, after vaccination with split vaccine (FluarixTM). Antibody titers have been determined by hemagglutination inhibition test (HI) against different influenza A and B drift variants in sera from three past multicenter trials. Individuals of two different age groups, i.e. 18–60 years and above 60 years, were enrolled. Vaccine components influenza A/H1N1 and influenza B of FluarixTM show a high degree of cross immunogenicity against subsequent homologous drift variants. The genetically more variable component influenza A/H3N2 shows somewhat lower protection rates. High levels of cross immunogenicity were found between the variants of influenza A/Panama/2007/99 (H3N2) and influenza A/Wyoming/3/2003 (H3N2). The results demonstrate that in situations where drift variants emerge too late to be included in the influenza vaccine formulation, the cross-protection conferred must be evaluated on a case-by-case basis.
Related content


Mechanism of Protection against Influenza A Virus by DNA Vaccine Encoding the Hemagglutinin Gene
Intervirology, Vol. 43, Iss. 4-6, 2001-02 ,pp. :






Factors associated with vaccination against influenza in the elderly
By Francisco Priscila Maria Stolses Bergamo Donalisio Maria Rita Barros Marilisa Berti de Azevedo César Chester Luis Galvão Carandina Luana Goldbaum Moisés
Revista Panamericana de Salud Pública/Pan American Journal of Public Health, Vol. 19, Iss. 4, 2006-04 ,pp. :